Telix Executive and Leadership Team

Michael Didocha, the Chief Financial Officer (Americas) at Telix, manages the financial health and capital allocation for the North American market. Overseeing regional fiscal planning, the Chief Financial Officer (Americas) ensures the company maintains the necessary liquidity to support the commercialization of PSMA-PET/CT imaging agents. This leadership role involves analyzing market trends to inform investment in urologic oncology and bone marrow conditioning programs. By optimizing financial reporting and tax strategies, Michael Didocha provides the transparency required for stakeholders and regulatory bodies. The Chief Financial Officer (Americas) collaborates with the global finance team to align regional performance with the broader corporate objectives of the organization. Through rigorous budget management and risk assessment, Didocha secures the financial stability required for sustained growth in the competitive biopharmaceutical landscape. Ultimately, the Chief Financial Officer (Americas) drives the fiscal discipline that enables the company to deliver life-saving diagnostic solutions to patients across the Americas.

Darren Patti, the Group Chief Operating Officer at Telix, executes the commercial strategy for the global portfolio of radiopharmaceuticals. Overseeing the operational execution of product launches, the Group Chief Operating Officer ensures alignment between manufacturing output and market demand for diagnostic and therapeutic agents. This leadership role involves managing cross-functional teams to optimize the commercialization of Illuccix across diverse regulatory environments. By refining internal processes, Darren Patti drives operational excellence and cost-efficiency throughout the organization. The Group Chief Operating Officer coordinates with regional leads to scale distribution networks, ensuring consistent availability of cancer imaging products. Through strategic resource allocation, Patti supports the long-term viability of the company pipeline, including urologic and musculoskeletal oncology programs. By maintaining high standards of operational performance, the Group Chief Operating Officer facilitates the transition of innovative therapies from clinical development to widespread clinical adoption, directly impacting the company's market position.

Paul Schaffer, the Chief Technology Officer at Telix, directs the research and development of advanced radiopharmaceutical platforms. Overseeing the technical integration of molecularly targeted radiation, the Chief Technology Officer ensures the pipeline remains at the forefront of urologic and neuro-oncology innovation. This leadership role involves managing complex laboratory infrastructure and scaling manufacturing processes to meet global demand for diagnostic agents. By optimizing the synthesis of theranostic compounds, Paul Schaffer directly impacts the efficiency of cancer imaging and treatment protocols. The Chief Technology Officer collaborates with scientific teams to refine the development of PSMA-PET/CT imaging agents, ensuring regulatory compliance and clinical efficacy. Through rigorous technical oversight, Schaffer maintains the competitive advantage of the company in the biopharmaceutical sector, driving the evolution of next-generation cancer therapies while supporting the broader mission of delivering precision medicine to patients worldwide.

Craig Ulrick, the Chief Information Officer at Telix, architects the digital infrastructure supporting global commercial-stage operations. Managing the secure data systems required for pharmaceutical distribution and regulatory reporting, the Chief Information Officer ensures seamless connectivity across international markets. This leadership role involves implementing robust cybersecurity frameworks to protect sensitive clinical trial data and proprietary research findings. By streamlining enterprise resource planning, Craig Ulrick enhances operational transparency and data-driven decision-making for the executive team. The Chief Information Officer integrates advanced analytics to monitor the supply chain of radiopharmaceuticals, ensuring timely delivery of diagnostic agents to healthcare providers. Through the deployment of scalable cloud solutions, Ulrick supports the rapid expansion of the company, facilitating efficient communication between global offices and manufacturing facilities. Ultimately, the Chief Information Officer secures the digital foundation necessary for the continued growth and market success of the organization.

David Cade, the Chief Medical Officer at Telix, directs the clinical development and medical strategy for the entire radiopharmaceutical pipeline. Overseeing the design and execution of clinical trials, the Chief Medical Officer ensures that all therapeutic and diagnostic candidates meet the highest standards of safety and efficacy. This leadership role involves engaging with global regulatory agencies to secure approvals for innovative cancer treatments. By providing medical oversight for the development of PSMA-PET/CT imaging agents, David Cade validates the clinical utility of the company's theranostic approach. The Chief Medical Officer collaborates with the research team to translate scientific breakthroughs into actionable patient care protocols. Through the management of medical affairs and clinical evidence generation, Cade supports the expansion of the company into new therapeutic areas like neuro-oncology and sarcoma. Ultimately, the Chief Medical Officer ensures that the medical mission remains central to the commercial success and clinical impact of the organization.